# LITHIUM CITRATE
> **ANDA218036** · Abbreviated New Drug Application (Generic) · Sponsor: RUBICON RESEARCH · Approved 2023-08-14
## Drug
- **FDA Application Number:** ANDA218036
- **Application type:** Abbreviated New Drug Application (Generic)
- **Brand name:** LITHIUM CITRATE
- **Generic name:** LITHIUM
- **Active ingredients:** LITHIUM CITRATE
- **Dosage form:** SYRUP
- **Route:** ORAL
- **Marketing status:** Prescription
- **Sponsor:** RUBICON RESEARCH
- **Manufacturer:** Advagen Pharma Ltd
- **First approval:** 2023-08-14
## Source
- [Drugs@FDA application overview](https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=218036)
---
*MORVS · CC0 1.0*